Transfer of Rights for Cetrorelix a Boon for Merck Serono

Transfer of Rights for Cetrorelix a Boon for Merck Serono

Used to regulate hormone responses in female patients undergoing infertility treatment, Cetrorelix, is also known as the brand name Cetrotide. On April 17, 2013 Aeterna Zentaris announced the transfer of the manufacturing rights of this powerhouse product to Merck Serono. With the patent for Cetrotide set to expire on April 23, 2019, this transfer of rights shows the vital importance of this essential infertility treatment. As a leader in the fertility treatment arena, Merck Serono excitedly took the reins for this effectual and leading medication.


Cetrorelix is available as a powder and solvent which is then made into a solution that is administered via injection. Cetrorelix is a reliable standard when treating women who are having ovarian stimulation. By preventing premature ovulation Cetrorelix aids patients by enacting a controlled and consistent ovarian stimulation that is typically followed by both oocyte pick-up and assisted reproductive technology.

Dispensed as an injection under the skin in the lower part of the patient’s abdomen, a physician usually injects Cetrotide during this portion of fertility treatment. The dosage is either 0.25 milligrams or 3 milligrams. A typical dosing schedule would be 0.25 milligrams injected once daily, in either the early morning or late afternoon at exactly 24 hour intervals. The treatment begins for most patients on either the fifth or sixth day of ovarian stimulation. Administration of Cetrorelix is then continued through the entire ovarian stimulation period, right up until the night before or sometimes the morning of the induction of ovulation is planned. The 3 milligram dose of Cetrorelix is one single dose administration given on the seventh day of ovarian stimulation. Some physicians may prefer to extend this particular dosing schedule with daily injections of 0.25 milligrams four days after the 3 milligram injection. Adverse effects are rare, and mild side effects of Cetrorelix may include overstimulated ovaries.

LGM Pharma provides Cetrorelix CAS number 120287-85-6 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service